RANI — Rani Therapeutics Holdings Income Statement
0.000.00%
- $155.29m
- $152.29m
Annual income statement for Rani Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.979 | 0.462 | 2.72 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 28 | 17 | 55 | 63.5 | 66.1 |
Operating Profit | -27.1 | -16.5 | -52.3 | -63.5 | -66.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -26.6 | -16.7 | -53 | -63.3 | -67.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -26.6 | -16.7 | -53.1 | -63.3 | -67.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -26.6 | -16.7 | -8.33 | -30.6 | -34 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.6 | -16.7 | -8.33 | -30.6 | -34 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.554 | -0.348 | -0.403 | -1.28 | -1.33 |
Dividends per Share |